Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure

Published:December 29, 2014DOI:



      Beta-blockers improve outcomes in patients with systolic heart failure. However, it is unknown whether their initial negative inotropic effect may increase 30-day all-cause readmission, a target outcome for Medicare cost reduction and financial penalty for hospitals under the Affordable Care Act.


      Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals (1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction <45%, 2202 were not previously on beta-blocker therapy, of which 383 received new discharge prescriptions for beta-blockers. Propensity scores for beta-blocker use, estimated for each of the 2202 patients, were used to assemble a matched cohort of 380 pairs of patients receiving and not receiving beta-blockers who were balanced on 36 baseline characteristics (mean age 73 years, mean ejection fraction 27%, 45% women, 33% African American).


      Beta-blocker use was not associated with 30-day all-cause readmission (hazard ratio [HR] 0.87; 95% confidence interval [CI], 0.64-1.18) or heart failure readmission (HR 0.95; 95% CI, 0.57-1.58), but was significantly associated with lower 30-day all-cause mortality (HR 0.29; 95% CI, 0.12-0.73). During 4-year postdischarge, those in the beta-blocker group had lower mortality (HR 0.81; 95% CI, 0.67-0.98) and combined outcome of all-cause mortality or all-cause readmission (HR 0.87; 95% CI, 0.74-0.97), but not with all-cause readmission (HR 0.89; 95% CI, 0.76-1.04).


      Among hospitalized older patients with systolic heart failure, discharge prescription of beta-blockers was associated with lower 30-day all-cause mortality and 4-year combined death or readmission outcomes without higher 30-day readmission.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jencks S.F.
        • Williams M.V.
        • Coleman E.A.
        Rehospitalizations among patients in the Medicare fee-for-service program.
        N Engl J Med. 2009; 360: 1418-1428
        • Jiang H.J.
        • Russo C.A.
        • Barrett M.L.
        Nationwide Frequency and Costs of Potentially Preventable Hospitalizations, 2006: Statistical Brief #72.
        Healthcare Cost and Utilization Project (HCUP), Rockville, MD2006
        • Packer M.
        • Bristow M.R.
        • Cohn J.N.
        • et al.
        The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
        N Engl J Med. 1996; 334: 1349-1355
        • Hjalmarson A.
        • Goldstein S.
        • Fagerberg B.
        • et al.
        Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
        JAMA. 2000; 283: 1295-1302
        • Hernandez A.F.
        • Hammill B.G.
        • O'Connor C.M.
        • Schulman K.A.
        • Curtis L.H.
        • Fonarow G.C.
        Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry.
        J Am Coll Cardiol. 2009; 53: 184-192
        • Feller M.A.
        • Mujib M.
        • Zhang Y.
        • et al.
        Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project.
        Int J Cardiol. 2012; 162: 39-44
        • Zhang Y.
        • Fonarow G.C.
        • Sanders P.W.
        • et al.
        A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age >/= 65 years.
        Am J Cardiol. 2011; 108: 1443-1448
        • Ahmed A.
        • Rich M.W.
        • Zile M.
        • et al.
        Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.
        Am J Med. 2013; 126: 150-161
        • Ahmed A.
        • Fonarow G.C.
        • Zhang Y.
        • et al.
        Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease.
        Am J Med. 2012; 125: 399-410
        • Rosenbaum P.R.
        • Rubin D.B.
        The central role of propensity score in observational studies for causal effects.
        Biometrika. 1983; 70: 41-55
        • Rubin D.B.
        Using propensity score to help design observational studies: application to the tobacco litigation.
        Health Serv Outcomes Res Methodol. 2001; 2: 169-188
        • Michels K.B.
        • Braunwald E.
        Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials.
        JAMA. 2002; 287: 3130-3132
        • Heinze G.
        • Juni P.
        An overview of the objectives of and the approaches to propensity score analyses.
        Eur Heart J. 2011; 32: 1704-1708
        • Ahmed A.
        • Husain A.
        • Love T.E.
        • et al.
        Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.
        Eur Heart J. 2006; 27: 1431-1439
        • Banach M.
        • Bhatia V.
        • Feller M.A.
        • et al.
        Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure.
        Am J Cardiol. 2011; 107: 1208-1214
        • Shariff N.
        • Desai R.V.
        • Patel K.
        • et al.
        Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation.
        Am J Med. 2013; 126: 887-893
        • Ahmed A.
        • Bourge R.C.
        • Fonarow G.C.
        • et al.
        Digoxin use and lower 30-day all-cause readmission for medicare beneficiaries hospitalized for heart failure.
        Am J Med. 2014; 127: 61-70
        • Austin P.C.
        Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review.
        Circ Cardiovasc Qual Outcomes. 2008; 1: 62-67
        • Gheorghiade M.
        • Fonarow G.C.
        • van Veldhuisen D.J.
        • et al.
        Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.
        Eur Heart J. 2013; 34: 1489-1497
        • Mujib M.
        • Patel K.
        • Fonarow G.C.
        • et al.
        Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.
        Am J Med. 2013; 126: 401-410
        • Patel K.
        • Fonarow G.C.
        • Kitzman D.W.
        • et al.
        Aldosterone Antagonists and Outcomes in Real-World Older Patients with Heart Failure and Preserved Ejection Fraction.
        JACC Heart Fail. 2013; 1: 40-47
        • Bello D.
        • Shah D.J.
        • Farah G.M.
        • et al.
        Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy.
        Circulation. 2003; 108: 1945-1953
        • Gwathmey J.K.
        • Kim C.S.
        • Hajjar R.J.
        • et al.
        Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol.
        Am J Physiol. 1999; 276: H1678-H1690
        • Hall S.A.
        • Cigarroa C.G.
        • Marcoux L.
        • Risser R.C.
        • Grayburn P.A.
        • Eichhorn E.J.
        Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.
        J Am Coll Cardiol. 1995; 25: 1154-1161
        • Ahmed A.
        • Fleg J.L.
        Heart failure in older adults.
        in: Aronow W.S. Flaherty J.D. Rich M.W. Tresch and Aronow's Cardiovascular Disease in the Elderly. 5th Ed. CRC Press; Taylor and Francis Group, Boca Raton, FL2013
        • Sanam K.
        • Bhatia V.
        • Parvataneni S.
        • et al.
        Discharge Initiation of ACE Inhibitors or ARBs is Associated with Significantly Lower 30-Day All-Cause Readmission in Hospitalized Older Patients with Heart Failure and Reduced Ejection Fraction.
        J Am Coll Cardiol. 2014; 63: A562
        • Carson P.
        • Anand I.
        • O'Connor C.
        • et al.
        Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
        J Am Coll Cardiol. 2005; 46: 2329-2334
        • Zile M.R.
        • Gaasch W.H.
        • Anand I.S.
        • et al.
        Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
        Circulation. 2010; 121: 1393-1405
        • Kheirbek R.E.
        • Alemi F.
        • Citron B.A.
        • Afaq M.A.
        • Wu H.
        • Fletcher R.D.
        Trajectory of illness for patients with congestive heart failure.
        J Palliat Med. 2013; 16: 478-484
        • O'Connor C.M.
        • Miller A.B.
        • Blair J.E.
        • et al.
        Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
        Am Heart J. 2010; 159: 841-849.e1
        • Konstam M.A.
        • Gheorghiade M.
        • Burnett Jr., J.C.
        • et al.
        Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
        JAMA. 2007; 297: 1319-1331
        • Krum H.
        • Roecker E.B.
        • Mohacsi P.
        • et al.
        Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
        JAMA. 2003; 289: 712-718
        • Butler J.
        • Arbogast P.G.
        • BeLue R.
        • et al.
        Outpatient adherence to beta-blocker therapy after acute myocardial infarction.
        J Am Coll Cardiol. 2002; 40: 1589-1595
        • Butler J.
        • Arbogast P.G.
        • Daugherty J.
        • Jain M.K.
        • Ray W.A.
        • Griffin M.R.
        Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.
        J Am Coll Cardiol. 2004; 43: 2036-2043
        • Curtis L.H.
        • Mi X.
        • Qualls L.G.
        • et al.
        Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure.
        Am Heart J. 2013; 165: 979-986.e1
        • Hunt S.A.
        • Abraham W.T.
        • Chin M.H.
        • et al.
        2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.
        Circulation. 2009; 119: e391-e479
        • Gattis W.A.
        • O'Connor C.M.
        • Gallup D.S.
        • et al.
        Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial.
        J Am Coll Cardiol. 2004; 43: 1534-1541
        • Clarke R.
        • Shipley M.
        • Lewington S.
        • et al.
        Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies.
        Am J Epidemiol. 1999; 150: 341-353
        • Mujib M.
        • Zhang Y.
        • Feller M.A.
        • Ahmed A.
        Evidence of a “heart failure belt” in the southeastern United States.
        Am J Cardiol. 2011; 107: 935-937